Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price target f...
BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $35 to $27.
Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $27 to $26.
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and co...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and c...
Mizuho analyst Joseph Catanzaro initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Outperform rating and announce...
HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $33 price ...
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $27 price target.
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immu...
